Attention: We no longer offer cytogenetic testing for all sample types and infectious study add-on testing for prenatal specimens. Please view the list of retired tests and FAQs here and contact us at with any questions.

Disease should be rare. Diagnosis shouldn't.

That’s the future we’re building at GeneDx.

We provide answers, so you can focus on care

Find the right diagnosis the first time.
Whole genome and exome testing offer a complete view of a patient’s genetic makeup and have a superior diagnostic yield to multi-gene panels. Additionally, more and more professional society guidelines support exome and genome testing as a first line test, particularly for epilepsy, intellectual disability/developmental delay, and congenital abnormalities. Starting complex disease patients with genome or exome testing means getting them to a diagnosis faster and saving patients and families years of unnecessary testing, heartache, and stress.
More accurate information means more effective treatment plans.
Our unique ability to analyze genomic information alongside comprehensive clinical datasets means patients are provided with an incredibly precise diagnosis.This enables patients to get the exact care they need, including connecting them to appropriate clinical trials or developing specialized care plans.
Science backed by support.
We are here for you and your patients throughout the entire testing process, from placing orders to interpreting results. Our dedicated team of genetic counselors provides peer-to-peer support as well as pre- and post-test counseling services. Also, our billing experts work with families on flexible and affordable payment plans so patients can get the care they need. With comprehensive care from start to finish, we offer more than just a test result.


Why GeneDx

We’re moving exome and genome from specialized tests to standard of care, improving patients’ lives by building towards a future where we can sequence DNA once and analyze the results for a lifetime.


We’re a leader in genomics, with over 400,000 clinical exome and genome tests interpreted and delivered. We offer premier expertise in exome sequencing for pediatric conditions and rare and ultra-rare genetic diseases.

Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence, allowing us to ingest and synthesize clinical and genomic data to deliver better health insights.

With one of the world’s largest rare disease data sets, we’re poised to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care.


Latest news

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
Mar 20, 2023

Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four Years


GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
March 16, 2023

New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey


GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 14, 2023

Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million